{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:14:23Z","timestamp":1792005263517,"version":"4.4.0"},"reference-count":22,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"unspecified","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2024,4,11]]},"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Compared with multiple-inhaler triple therapy (MITT), single-inhaler triple therapy (SITT) with fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI) demonstrated improved lung function and meaningful improvements in chronic obstructive pulmonary disease (COPD) Assessment Test score. This real-world study compared the effectiveness of switching patients with COPD in England from MITT to once-daily SITT with FF\/UMEC\/VI by evaluating rates of COPD exacerbation, healthcare resource use (HCRU) and associated direct medical costs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Retrospective cohort pre-post study using linked primary care electronic health record and secondary care administrative datasets. Patients diagnosed with COPD at age \u226535 years, with smoking history, linkage to secondary care data and continuous GP registration for 12 months pre-switch and 6 months post-switch to FF\/UMEC\/VI were included. Index date was the first initiation of an FF\/UMEC\/VI prescription immediately following MITT use from 15 November 2017 to 30 September 2019. Baseline was 12 months prior to index, with outcomes assessed 6\/12 months pre-switch and post-switch, and stratified by prior COPD exacerbation status.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 2533 patients (mean [SD] age: 71.1 [9.9] years; 52.1% male). In the 6 months post-switch, there were significant decreases in the proportion of patients experiencing \u22651 moderate-to-severe (36.2%\u201328.9%), moderate only (24.4%\u201319.8%) and severe only (15.4%\u201311.8%) COPD exacerbation (each, p&lt;0.0001) compared with the 6 months pre-switch. As demonstrated by rate ratios, there were significant reductions in exacerbation rates of each severity overall (p&lt;0.01) and among patients with prior exacerbations (p&lt;0.0001). In the same period, there were significant decreases in the rate of each COPD-related HCRU and total COPD-related costs (\u221224.9%; p&lt;0.0001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Patients with COPD switching from MITT to once-daily SITT with FF\/UMEC\/VI in a primary care setting had significantly fewer moderate and severe exacerbations, and lower COPD-related HCRU and costs, in the 6 months post-switch compared with the 6 months pre-switch.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjresp-2023-001890","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T22:56:12Z","timestamp":1716332172000},"page":"e001890","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort study"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4279-1624","authenticated-orcid":false,"given":"Kieran J","family":"Rothnie","sequence":"first","affiliation":[{"name":"Value Evidence and Outcomes, GSK, Brentford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6977-435X","authenticated-orcid":false,"given":"Robert P","family":"Wood","sequence":"additional","affiliation":[{"name":"Real-World Evidence, Adelphi Real World, Bollington, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3395-6186","authenticated-orcid":false,"given":"Alexandrosz","family":"Czira","sequence":"additional","affiliation":[{"name":"Value Evidence and Outcomes, GSK, Brentford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0087-7641","authenticated-orcid":false,"given":"Victoria L","family":"Banks","sequence":"additional","affiliation":[{"name":"Real-World Evidence, Adelphi Real World, Bollington, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8056-054X","authenticated-orcid":false,"given":"Lucinda J","family":"Camidge","sequence":"additional","affiliation":[{"name":"Real-World Evidence, Adelphi Real World, Bollington, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia K I","family":"Massey","sequence":"additional","affiliation":[{"name":"Real-World Evidence, Adelphi Real World, Bollington, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Seif","sequence":"additional","affiliation":[{"name":"Real-World Evidence, Adelphi Real World, Bollington, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7564-5343","authenticated-orcid":false,"given":"Chris","family":"Compton","sequence":"additional","affiliation":[{"name":"Global Medical, GSK, Brentford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Sharma","sequence":"additional","affiliation":[{"name":"Global Medical, GSK, Brentford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2009-4406","authenticated-orcid":false,"given":"David M G","family":"Halpin","sequence":"additional","affiliation":[{"name":"University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2876-8308","authenticated-orcid":false,"given":"Afisi S","family":"Ismaila","sequence":"additional","affiliation":[{"name":"Value Evidence and Outcomes, GSK, Collegeville, PA, USA"},{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9798-2527","authenticated-orcid":false,"given":"Claus F","family":"Vogelmeier","sequence":"additional","affiliation":[{"name":"Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Centre Giessen and Marburg, Philipps-University Marburg, German Center for Lung Research (DZL), Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"2025083109421861000_11.1.e001890.1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2022. Available: https:\/\/goldcopd.org\/2022-gold-reports\/ [Accessed 28 Feb 2023]."},{"key":"2025083109421861000_11.1.e001890.2","unstructured":"European Medicines Agency . Trelegy Ellipta. 2022. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/trelegy-ellipta [Accessed 28 Feb 2023]."},{"key":"2025083109421861000_11.1.e001890.3","doi-asserted-by":"crossref","first-page":"106807","DOI":"10.1016\/j.rmed.2022.106807","article-title":"Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: a real-world study","volume":"197","author":"Mannino","year":"2022","journal-title":"Respir Med"},{"key":"2025083109421861000_11.1.e001890.4","article-title":"Are patients with COPD more adherent to single-inhaler compared with multiple-inhaler triple therapy in a real-world UK primary care treated population?","volume":"58","author":"Rothnie","year":"2021","journal-title":"Eur Respir J"},{"key":"2025083109421861000_11.1.e001890.5","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00950-2020","article-title":"INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice","volume":"7","author":"Halpin","year":"2021","journal-title":"ERJ Open Res"},{"key":"2025083109421861000_11.1.e001890.6","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.2147\/COPD.S370540","article-title":"Comparative adherence and persistence of single- and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in an English real-world primary care setting","volume":"17","author":"Halpin","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025083109421861000_11.1.e001890.7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2147\/COPD.S378867","article-title":"COPD exacerbations, costs, and health care resource utilization before and after initiation of Fluticasone Furoate\/Umeclidinium\/Vilanterol in routine care in the USA","volume":"18","author":"Hanania","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025083109421861000_11.1.e001890.8","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz034"},{"key":"2025083109421861000_11.1.e001890.9","unstructured":"MHRA . Release notes: CPRD Aurum September 2022. 2022. Available: https:\/\/cprd.com\/sites\/default\/files\/2022-09\/2022-09%20CPRD%20Aurum%20Release%20Notes.pdf [Accessed 28 Feb 2023]."},{"key":"2025083109421861000_11.1.e001890.10","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-018-0442-4"},{"key":"2025083109421861000_11.1.e001890.11","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyx015"},{"key":"2025083109421861000_11.1.e001890.12","unstructured":"National Institute for Health and Care Excellence . Chronic obstructive pulmonary disease in over 16s: diagnosis and management. 2019. Available: https:\/\/www.nice.org.uk\/guidance\/ng115\/chapter\/Recommendations [Accessed 28 Feb 2023]."},{"key":"2025083109421861000_11.1.e001890.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151357","article-title":"Validation of the recording of acute exacerbations of COPD in UK primary care electronic healthcare records","volume":"11","author":"Rothnie","year":"2016","journal-title":"PLoS One"},{"key":"2025083109421861000_11.1.e001890.14","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S117867"},{"key":"2025083109421861000_11.1.e001890.15","unstructured":"Personal Social Services Research Unit . Unit costs of health and social care. 2020. Available: https:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/ [Accessed 6 Mar 2024]."},{"key":"2025083109421861000_11.1.e001890.16","unstructured":"National Health Service . National tariff payment system 2017\/18 and 2018\/19. NHS Improvement. Available: https:\/\/www.england.nhs.uk\/#h2-201920-national-tariff-payment-system [Accessed 6 Mar 2024]."},{"key":"2025083109421861000_11.1.e001890.17","unstructured":"National Health Service Business Service Authority . Drug tariff. Available: https:\/\/www.nhsbsa.nhs.uk\/pharmacies-gp-practices-and-appliance-contractors\/drug-tariff [Accessed 6 Mar 2024]."},{"key":"2025083109421861000_11.1.e001890.18","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2147\/COPD.S338436","article-title":"Characteristics of new users of single- and multiple-inhaler triple therapy for COPD in primary care in England","volume":"17","author":"Rothnie","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025083109421861000_11.1.e001890.19","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.2147\/COPD.S370577","article-title":"Cost-effectiveness of single- versus multiple-inhaler triple therapy in a UK COPD population: the INTREPID trial","volume":"17","author":"Halpin","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025083109421861000_11.1.e001890.20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000363771","article-title":"The importance of continuity in Inhaler device choice for asthma and chronic obstructive pulmonary disease","volume":"88","author":"Bjermer","year":"2014","journal-title":"Respiration"},{"key":"2025083109421861000_11.1.e001890.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-023-02523-1","article-title":"Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF\/UMEC\/VI) in patients with COPD in England following an exacerbation \u2013 a retrospective cohort study","volume":"24","author":"Ismaila","year":"2023","journal-title":"Respir Res"},{"key":"2025083109421861000_11.1.e001890.22","doi-asserted-by":"crossref","unstructured":"Torgerson DJ , Torgerson CJ . The limitations of before and after designs. In: Designing Randomised Trials in Health, Education and the Social Sciences. London: Palgrave Macmillan, 2008.","DOI":"10.1057\/9780230583993"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2023-001890","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T16:42:30Z","timestamp":1756658550000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2023-001890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,5,21]]},"published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1136\/bmjresp-2023-001890"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2023-001890","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}